Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone inhibits CYP17A1, blocks androgen synthesis, and prolongs survival in prostate cancer.
GNF179 Metabolite, the derivative of GNF179—an optimized 8,8-dimethyl IP analog—demonstrates significant potency (4.8 nM against the multidrug-resistant W2 strain) alongside in vitro metabolic stability and in vivo oral bioavailability.